trending Market Intelligence /marketintelligence/en/news-insights/trending/ugs4ftumble9edevppmzfg2 content esgSubNav
In This List

Court dismisses Amgen patent case against Coherus' biosimilar

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Court dismisses Amgen patent case against Coherus' biosimilar

A U.S. federal court dismissed Amgen Inc.'s patent lawsuit against Coherus Biosciences Inc. for failing to state a claim upon which relief may be granted.

Amgen had alleged before the U.S. District Court for the District of Delaware that Coherus' biosimilar medicine CHS-1701 infringed on its patents covering the medicine Neulasta, which is also known as pegfilgrastim.

The drug helps in the growth of new white blood cells, which protects against the risk of infection following chemotherapy. It helped generate $4.53 billion in 2017 revenues for Amgen, including $3.93 billion from the U.S. alone.

Coherus has been looking to market a cheaper version of the medicine, though the U.S. Food and Drug Administration has asked the company to provide additional data before it can approve the biosimilar. The regulator's rejection of its biologics license application for CHS-1701 prompted the company to cut its workforce by about 30%.

The company also expects the European Medicines Agency to make a decision on its application for CHS-1701 sometime later this year.